COVID-19: How, What, When, and WherePage 8 of 13

6. Vaccines and Therapeutics

Immunity is the ability of the human body to tolerate substances indigenous to the body and to eliminate foreign substances. Immunity is generally specific to a single organism or group of closely related organisms. The ability to eliminate foreign substances lies in the immune system. Since most organisms are identified as foreign, the ability to identify and eliminate these substances provides protection from infectious disease (Pink Book, 2020, June 29).

The immune system develops a defense against foreign substances. This defense is known as the immune response and usually involves the production of protein molecules (immunoglobulins or antibodies) by B-lymphocytes (B-cells) and specific cells, including T-lymphocytes (Pink Book, 2020, June 29).

The most effective immune responses are generally produced in response to antigens present in a live organism; however, an antigen does not necessarily have to be present in a live organism to produce an immune response. Some antigens, such as hepatitis B surface antigen, are easily recognized by the immune system and produce adequate protection. In some cases, the immune response may not provide good protection.

Vaccines stimulate the immune system to produce immune responses that protect against infection. Vaccines provide a safe, cost-effective, and efficient means of preventing illness, disability, and death from infectious diseases.

Did You Know. . .

In late July 2020, NIAID reported that two doses of an experimental vaccine to prevent COVID-19 induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2. The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts (NIAID, 2020, July 28).


There is more than one type of vaccine, although each is designed to teach the immune system how to fight off certain kinds of pathogens—and the serious diseases they cause. Types of vaccines include:

  • Live-attenuated vaccines
  • Inactivated vaccines
  • Subunit, recombinant, polysaccharide, and conjugate vaccines
  • Nucleic acid vaccines

Live-attenuated and Inactivated Vaccines

[Unless otherwise noted, the information in the following sections is taken from NIAID, Vaccine Types, July 1, 2019]

Traditional vaccines consist of entire pathogens that have been killed or weakened so that they cannot cause disease. Such whole-pathogen vaccines can elicit strong protective immune responses. Many of the vaccines in clinical use today fall into this category. However, not every disease-causing microbe can be effectively targeted with a whole-pathogen vaccine.

Did You Know. . .

The more similar a vaccine is to the disease-causing form of the organism, the better the immune response to the vaccine.

Measles Particle

Microscopic Image of a Single Measles Virus Particle

In 1954 Thomas Peebles and John Enders collected blood from students with measles at a private school near Boston. The measles virus was isolated and used to create a series of vaccines. The picture shows a thin-section transmission electron microscopic image of a single measles virus particle, with the viral nucleocapsid situated underneath the viral envelope, surrounded by surface projections. Source: Courtesy of CDC/Cynthia S. Goldsmith; and William Bellini, Ph.D. Used by permission.

Advances in tissue culture techniques have enabled development of live-attenuated vaccines, which contain a version of the living microbe that has been weakened in the laboratory. These vaccines elicit strong immune responses and can confer life-long immunity after only one or two doses. Live-attenuated vaccines are relatively easy to create for certain viruses, but difficult to produce for more complex pathogens like bacteria and parasites. Live vaccines are used to protect against:

  • Measles, mumps, rubella (MMR combined vaccine)
  • Rotavirus
  • Smallpox
  • Chickenpox
  • Yellow fever

Inactivated, or killed, microbes have the ability to induce immunity. These inactivated vaccines are produced by killing the pathogen with chemicals, heat, or radiation. Inactivated vaccines usually do not provide immunity that is as strong as live vaccines. Several doses over time (booster shots) may be needed to get ongoing immunity against diseases. Inactivated vaccines are used to protect against:

  • Hepatitis A
  • Flu (shot only)
  • Polio (shot only)
  • Rabies

Child Receiving a Flu Shot

A child receiving a flu shot. Source: Shutterstock.

Modern genetic engineering techniques have enabled creation of chimeric viruses, which contain genetic information from, and display biologic properties of, different parent viruses. A NIAID-developed live-attenuated chimeric vaccine consisting of a dengue virus backbone with Zika virus surface proteins is undergoing early-stage testing in humans.

Subunit Recombinant, Polysaccharide, and Conjugate Vaccines

In a difference from the entire pathogen, subunit vaccines include only the components, or antigens, that best stimulate the immune system. Although this design can make vaccines safer and easier to produce, it often requires the incorporation of adjuvants* to elicit a strong protective immune response because the antigens alone are not sufficient to induce adequate long-term immunity.

*Adjuvants: substances formulated as part of a vaccine to boost immune responses and enhance the vaccine’s effectiveness.

Including only the essential antigens in a vaccine can minimize side effects, as illustrated by the development of a new generation of pertussis vaccines. The first pertussis vaccines, introduced in the 1940s, contained inactivated Bordetella pertussis bacteria. Although effective, whole-cell pertussis vaccines frequently caused minor adverse reactions such as fever and swelling at the injection site. This caused many people to avoid the vaccine, and by the 1970s decreasing vaccination rates had brought about an increase in new infections. Research led to the development of acellular pertussis vaccines that are based on individual, purified B. pertussis components. These vaccines are similarly effective to whole-cell vaccines but much less likely to cause adverse reactions.

Some vaccines to prevent bacterial infections are based on the polysaccharides, or sugars, that form the outer coating of many bacteria. The first licensed vaccine against Haemophilus influenzae type B (Hib) was a polysaccharide vaccine. However, its usefulness was limited because it did not elicit strong immune responses in infants—the age group with the highest incidence of Hib disease. Researchers then developed a so-called conjugate vaccine in which the Hib polysaccharide is attached, or conjugated, to a protein antigen to offer improved protection. This formulation greatly increased the ability of the immune systems of young children to recognize the polysaccharide and develop immunity.

Other vaccines against bacterial illnesses, such as diphtheria and tetanus vaccines, aim to elicit immune responses against toxins (disease-causing proteins) secreted by the bacteria. The antigens in these so-called toxoid vaccines are chemically inactivated toxins, known as toxoids.

In the 1970s, advances in laboratory techniques ushered in the era of genetic engineering. A decade later, recombinant DNA technology—which enables DNA from two or more sources to be combined—was harnessed to develop the first recombinant protein vaccine, the hepatitis B vaccine. The vaccine antigen is a hepatitis B virus protein produced by yeast cells into which the genetic code for the viral protein has been inserted.

Vaccines to prevent human papillomavirus (HPV) infection also are based on recombinant protein antigens. In the early 1990s, scientists discovered that proteins from the outer shell of HPV can form particles that closely resemble the virus. These virus-like particles prompt an immune response similar to that elicited by the natural virus, but the virus-like particles are non-infectious because they do not contain the genetic material the virus needs to replicate inside cells.

Scientists are also developing new strategies to present protein subunit antigens to the immune system. As part of efforts to develop a universal flu vaccine, NIAID scientists designed an experimental vaccine featuring the protein ferritin, which can self-assemble into microscopic pieces called nanoparticles that display a protein antigen. An experimental nanoparticle-based influenza vaccine is being evaluated in an early-stage trial in humans.

Other relatively recent advances in laboratory techniques, such as the ability to solve atomic structures of proteins, have contributed to advances in subunit vaccine development. For example, by solving the three-dimensional structure of a protein on the RSV surface bound to an antibody, NIAID scientists identified a key area of the protein that is highly sensitive to neutralizing antibodies. They were then able to modify the RSV protein to stabilize the structural form it displays in the neutralization-sensitive site.

Antibody Binding to Virus

Illustration of Antibody Binding to Virus

Illustration of an antibody binding to the surface of a virus, blocking entry into a person’s cells. Credit: Courtesy of Lisa Donohue, CoVPN, and COVID-19 Prevention Network. Used by permission.

While most subunit vaccines focus on a particular pathogen, scientists also are developing vaccines that could offer broad protection against various diseases. In 2017 scientists launched an early-phase clinical trial of a vaccine to prevent mosquito-borne diseases such as malaria, Zika, chikungunya, and dengue fever. The experimental vaccine, designed to trigger an immune response to mosquito saliva rather than a specific virus or parasite, contains four recombinant proteins from mosquito salivary glands.

Subunit, recombinant, polysaccharide, and conjugate vaccines are used to protect against:

  • Hib (Haemophilus influenzae type b) disease
  • Hepatitis B
  • HPV (Human papillomavirus)
  • Whooping cough (part of the DTaP combined vaccine)
  • Pneumococcal disease
  • Meningococcal disease
  • Shingles

Nucleic Acid Vaccines

Another investigational approach to vaccination involves introducing genetic material encoding the antigen or antigens against which an immune response is sought. The body’s own cells then use this genetic material to produce the antigens. Potential advantages of this approach include the stimulation of broad long-term immune responses, excellent vaccine stability, and relative ease of large-scale vaccine manufacture. Many such vaccines are in the research pipeline, although none are currently licensed for human use.

DNA Vaccines

DNA plasmid vaccines comprise a small circular piece of DNA called a plasmid that carries genes encoding proteins from the pathogen of interest. The manufacturing process for DNA plasmid vaccines is well-established, allowing experimental vaccines to be quickly developed to address emerging or re-emerging infectious diseases. NIAID’s Vaccine Research Center has developed candidate DNA vaccines to address several viral disease threats during outbreaks, including SARS-CoV-1 in 2003, H5N1 avian influenza in 2005, H1N1 pandemic influenza in 2009, and Zika virus in 2016. The time from selection of the viral genes to be included in the vaccine to initiation of clinical studies in humans was shortened from 20 months with SARS-CoV-1 to slightly longer than 3 months with Zika virus.

Messenger RNA (mRNA) Vaccines

Vaccines based on messenger RNA (mRNA), an intermediary between DNA and protein, are also being developed. Recent technologic advances have largely overcome issues with the instability of mRNA and the difficulty of delivering it into cells, and some mRNA vaccines have demonstrated encouraging early results. For example, NIAID-supported researchers developed an experimental mRNA vaccine that protected mice and monkeys against Zika virus infection after a single dose.

RNA scientists believe mRNA vaccine can be a suitable solution in a time-pressed pandemic because the mRNAs can serve as instruction molecules to direct a person’s immune system to make their own protein reserve to combat a viral invasion. In this sense, recipients use the immune cells within their own bodies as a manufacturing hub for antibodies, rather than relying on external manufacturing capabilities, which is expected to save time when compared to traditional ways of manufacturing vaccines (Chin, 2020, July 20).

mRNA vaccines have other key advantages over traditional vaccines or DNA-based vaccine. The first and foremost is safety. mRNA is noninfectious, so it will not be integrated into the recipient’s genome and it can be digested by normal cellular processes. Through various chemical modifications, the longevity of these mRNAs in the body can be controlled (Chin, 2020, July 20).

In addition, the efficiency of mRNA delivery can be increased through designing and packaging the mRNA into protective carrier molecules, which would enhance stability and encourage rapid uptake by the cells. Furthermore, mRNA vaccine can not only be a rapid alternative but it is also scalable, as it relies on in vitro transcriptions (chemical reactions that are commonly practiced in laboratories) rather than on external factors such as the availability of hen’s eggs and the need for laboratory manipulation (Chin, 2020, July 20).

Rather than delivering DNA or mRNA directly to cells, some vaccines use a harmless virus or bacterium as a vector, or carrier, to introduce genetic material into cells. Several such recombinant vector vaccines are approved to protect animals from infectious diseases, including rabies and distemper. Many of these veterinary vaccines are based on a technology that uses weakened versions of a poxvirus to deliver the pathogen’s genetic material. Today, NIAID-supported scientists are developing and evaluating recombinant vectored vaccines to protect humans from viruses such as HIV, Zika virus, and Ebola virus.

COVID-19 mRNA Vaccines

On November 16, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 (manufactured by Moderna) reviewed trial data and shared its interim analysis with the trial oversight group. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers. The DSMB reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%. The findings are statistically significant, meaning they are likely not due to chance. Ninety of the cases occurred in the placebo group and 5 occurred in the vaccinated group. There were 11 cases of severe COVID-19 out of the 95 total, all of which occurred in the placebo group (NIH, 2020, November 16).

On December 10, 2020, an independent panel of medical experts recommended authorization of a Pfizer-BioNTech coronavirus vaccine on an emergency basis. The panel said that based on the available scientific evidence, the benefits of vaccination with the new mRNA vaccine outweigh the risks. Upon issuance of an emergency use authorization (EUA) by the Food and Drug Administration, inoculations are expected to begin in a few days.

On December 11, 2020, the FDA issued an emergency use authorization for the Pfizer-BioNTech coronavirus vaccine, clearing the way for vaccinations to begin in a matter of days. For more information please check out our COVID-19 Blog.

On December 18, 2020, the FDA granted an emergency use authorization for a COVID-19 vaccine developed by Moderna. It follows closely on the footsteps of the Pfizer-BioNTech vaccine and is expected to be available within a few days. The Moderna vaccine is for use in adults 18 years of age and older.

Additional COVID-19 Vaccines

On December 28, 2020, NIH announced the Phase 3 trial of another investigational COVID-19 vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. The National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA), are funding the trial (NIH, 2020, December 28).

“Addressing the unprecedented health crisis of COVID-19 has required extraordinary efforts on the part of government, academia, industry and the community,” said NIAID Director Anthony S. Fauci, M.D. “The launch of this study — the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States — demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines” (NIH, 2020, December 28).

Novavax’s investigational vaccine, NVX-CoV2373, is made from a stabilized form of the coronavirus spike protein using the company’s recombinant protein nanoparticle technology. The purified protein antigens in the vaccine cannot replicate and cannot cause COVID-19. The vaccine also contains a proprietary adjuvant, MatrixM™. In animal tests, NVX-CoV2373 vaccination produced antibodies that blocked the coronavirus spike protein from binding to the cell surface receptors targeted by the virus, preventing viral infection (NIH, 2020, December 28).

Vaccine Adjuvants

[Unless otherwise noted, the following information is from NIAID, Vaccine Adjuvants, July 2, 2019.]

Efforts to develop safe and effective vaccines increasingly involve the use of adjuvants—substances formulated as part of a vaccine to boost immune responses and enhance the vaccine’s effectiveness. Adjuvants help the body to produce an immune response strong enough to protect people from the disease they are being vaccinated against. Adjuvanted vaccines can cause more local reactions (such as redness, swelling, and pain at the injection site) and more systemic reactions (such as fever, chills and body aches) than non-adjuvanted vaccines.

Vaccine adjuvants accelerate, enhance, and prolong the immune responses triggered by antigens—the vaccine components that elicit pathogen-specific immune responses. Certain populations, such as people with compromised immune systems, elders, and the very young particularly benefit from vaccines with adjuvants because their immune systems may require an extra boost to provide protection. Adjuvants can also allow vaccine developers to use less antigen, which in some cases may be in short supply, or costly. Moreover, adjuvanted vaccines can elicit more durable immune responses, reducing or eliminating the need for booster vaccinations.

Aluminum-containing adjuvants, collectively termed alum, have been safely used in vaccines since the 1930s and are still widely used today. Aluminum is among the most common metals found in nature and is present in food and water. Scientific research has shown that the trace amounts of aluminum in vaccines are safe and not readily absorbed by the body.

For many years, alum was the only adjuvant added to vaccines in the United States. In recent decades, however, scientific advances have increased our understanding of human immunity, and these insights have led to the identification of new adjuvants and promising adjuvant candidates. In 2009 FDA-approved Cervarix, a human papillomavirus vaccine containing a novel adjuvant called AS04. Since then, several additional vaccines containing novel adjuvants have been approved for use in the United States.

Learning more about how adjuvants work to stimulate specific immune responses is critical to the development of new and improved vaccines. Adjuvant research lays a foundation for vaccine developers to improve the protection that current vaccines offer, design vaccines for emerging infectious diseases, expedite efforts to develop vaccines to protect against diseases without preventive inoculations (e.g., HIV, tuberculosis), and develop vaccines to treat allergies, autoimmune diseases, and cancer.

What Happens If We Stop Vaccinating?

Before the middle of the last century, diseases like whooping cough, polio, measles, flu, and rubella struck hundreds of thousands of infants, children, and adults in the United States. Thousands died every year from them. As vaccines were developed and became widely used, rates of these diseases declined, until today most of them are nearly gone from our country (CDC, 2018, June 29).

  • Before there was a vaccine, nearly everyone in the United States got measles, and hundreds died from it each year. Today, most doctors have never seen a case of measles.
  • More than 15,000 Americans died from diphtheria in 1921, before there was a vaccine. Only 2 cases of diphtheria have been reported to CDC between 2004 and 2014.
  • An epidemic of rubella (German measles) in 1964–1965 infected 12½ million Americans, killed 2,000 babies, and caused 11,000 miscarriages. Since 2012, 15 cases of rubella were reported to CDC. (CDC, 2018, June 29)

Illustration: How High Vaccination Rates Protect a Community

If one or two cases of disease are introduced into a community where most people are not vaccinated, outbreaks will occur. In 2013, for example, several measles outbreaks occurred around the country, including large outbreaks in New York City and Texas—mainly among groups with low vaccination rates. If vaccination rates dropped to low levels nationally, diseases could become as common as they were before vaccines. Source: CDC, 2018.

Anti-Viral, Immune-based, and Adjunctive Therapies

The COVID-19 pandemic has led to a global struggle to cope with the sheer numbers of infected people, many of whom require intensive care. The outbreak has been managed by a combination of public health measures and supportive care for those who are affected. To date, there is no specific anti–COVID-19 treatment. However, the urgency to identify supportive treatments has led to the emergence of several investigational drugs as potential candidates to improve outcomes, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional groups have attempted to clarify situations where the use of these drugs may be considered as off-label or compassionate (Xu et al., 2020).

Antiviral Drugs

Antiviral therapies inhibit viral entry, viral membrane fusion, and endocytosis.* Because viral replication may be particularly active early in the course of COVID-19, antiviral therapy may have the greatest impact before the illness progresses into the hyperinflammatory state seen in later stages of the disease. For this reason, understanding the role of antivirals in treating mild, moderate, severe, and critical illness is necessary to optimize treatment for people with COVID-19 (NIAID-RML, 2020, July 30).

*Endocytosis: a cellular process by which substances are brought into the cell. It is a type of active transport that moves particles, such as large molecules, parts of cells, and even whole cells, into a cell.

Remdesivir is an IV investigational treatment. It inhibits viral replication through premature termination of RNA transcription. It has demonstrated in vitro activity against SARS-CoV-2 (NIAID-RML, 2020, July 30).

On October 9, 2020, the COVID-19 Treatment Guidelines panel updated its recommendations for the use of remdesivir in hospitalized patients with COVID-19. For patients with who are not hospitalized or who are hospitalized with moderate disease but do not require supplemental oxygen, there are insufficient data for the Panel to recommend either for or against the use of remdesivir for the treatment of COVID-19. The Panel recognizes there may be situations in which a clinician judges that remdesivir is an appropriate treatment for a hospitalized patient with moderate disease (e.g., a person who is at a particularly high risk for clinical deterioration) (NIAID-RML, 2020, October 9, 2020).

For hospitalized patients with COVID-19 who require supplemental oxygen but who do not require delivery of oxygen through a high-flow device, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), Panel recommendations include:

  • Remdesivir 200 mg intravenously (IV) for 1 day, followed by remdesivir 100 mg IV for 4 days or until hospital discharge, whichever comes first (AI)or
  • A combination of remdesivir (dose and duration as above) plus dexamethasone 6 mg IV or orally for up to 10 days or until hospital discharge (BIII)or
  • If remdesivir cannot be used, dexamethasone may be used instead. (NIAID-RML, October 9, 2020)

Pharmacologic management of patients with COVID-19 based on disease severity.

Source: COVID-19 Treatment Guidelines, NIAID

On December 11, 2020, NIAID published the results of a clinical trail indicating that the combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19. Baricitinib was discovered by Incyte and licensed to Eli Lilly and Company, and marketed under the brand name Olumiant. It is approved in more than 70 countries as a treatment for adults with moderately-to-severely active rheumatoid arthritis. Researchers hypothesized that because many severe symptoms of COVID-19 are caused by a poorly regulated inflammatory response, a therapeutic designed to target inflammation could be helpful for patients (NIAID, 2020, December 11).

In the study, the combination of baricitinib and remdesivir reduced median time to recovery in hospitalized COVID-19 patients from eight days to seven days. Patients who required high-flow oxygen or non-invasive ventilation during their hospitalization appeared to have had the largest benefit: their median time to recovery was shortened from 18 days to ten days. In addition, participants’ conditions at day 15 of the study (as measured by an eight-category ordinal scale which ranked the severity of their condition) was significantly improved when they received the two therapeutics combined. Recipients of the two treatments also had slightly fewer serious adverse effects (NIAID, 2020, December 11).

Immune-based Therapies

Given the hyperactive inflammatory effects of SARS-CoV-2, agents that modulate the immune response are being explored as adjunctive treatments for the management of moderate to critical COVID-19. These agents include human blood–derived products and immunomodulatory therapies (NIAID-RML, 2020, July 30).

Some human blood–derived products are obtained from individuals who have recovered from SARS-CoV-2 infection (e.g., convalescent plasma, immunoglobulin products). These products are thought to have either direct antiviral properties, such as in convalescent plasma, and/or immunomodulatory effects. Additionally, neutralizing monoclonal antibodies directed against SARS-CoV-2 have been developed and are under investigation in clinical trials (NIAID-RML, 2020, July 30).

Other agents in this group include therapeutics currently approved for the treatment of other immune and/or inflammatory syndromes. These agents include corticosteroids (e.g., glucocorticoids), which as a class possess a broad array of mechanisms to treat systemic inflammation, and more targeted anti-inflammatory treatments such as interleukin inhibitors, interferons, kinase inhibitors, and others (NIAID-RML, 2020, July 30).

Adjunctive Therapies

Antithrombotic Therapy. Infection with SARS-CoV-2 has been associated with inflammation and a prothrombotic state, with increases in fibrin, fibrin degradation products, fibrinogen, and D-dimers. In fact, these markers have been associated with worsened clinical outcomes. Although the true incidence of these complications among those with differing severities of disease is not completely defined, there have been reports of increased incidence of thromboembolic disease associated with COVID-19 in patients in the intensive care unit.

For a summary of the use of antithrombotic therapy in patients with COVID-19, please go here.

Vitamin C. Vitamin C (ascorbic acid) is a water-soluble vitamin that is thought to have beneficial effects in patients with severe and critical illnesses. It is an antioxidant and free radical scavenger that has anti-inflammatory properties, influences cellular immunity and vascular integrity, and serves as a cofactor in the generation of endogenous catecholamines (NIAID-RML, 2020, July 30).

Because humans may require more vitamin C in states of oxidative stress, vitamin C supplementation has been evaluated in numerous disease states, including serious infections and sepsis. Because serious COVID-19 may cause sepsis and acute respiratory distress syndrome (ARDS),researchers are studying the potential role of high doses of vitamin C in ameliorating inflammation and vascular injury in patients with COVID-19. Nevertheless, insufficient data are available for the COVID-19 Treatment Guidelines panel to recommend either for or against the use of vitamin C for treatment of COVID-19 in noncritically ill patients (NIAID-RML, 2020, July 30).

Vitamin D. Vitamin D is critical for bone and mineral metabolism. Because the vitamin D receptor is expressed on immune cells such as B cells, T cells, and antigen-presenting cells, and because these cells can synthesize the active vitamin D metabolite, vitamin D also has the potential to modulate innate and adaptive immune responses (NIAID-RML, 2020, July 30).

Vitamin D deficiency is common in the United States, particularly among Black persons or those of Hispanic ethnicity. Vitamin D deficiency is also more common in older patients and patients with obesity and hypertension; these factors have been associated with worsened outcomes in patients with COVID-19. In observational studies, low vitamin D levels have been associated with an increased risk of community-acquired pneumonia in older adults and children. Vitamin D supplements may increase the levels of T regulatory cells in healthy individuals and patients with autoimmune diseases; vitamin D supplements may also increase T regulatory cell activity (NIAID-RML, 2020, July 30).

In a meta-analysis of randomized clinical trials, vitamin D supplementation was shown to protect against acute respiratory tract infection. However, in two randomized, double-blind, placebo-controlled clinical trials, administering high doses of vitamin D to critically ill patients with vitamin D deficiency (but not COVID-19) did not reduce the length of the hospital stay or the mortality rate when compared to placebo. High levels of vitamin D may cause hypercalcemia and nephrocalcinosis. Overall, insufficient data exist to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19 (NIAID-RML, 2020, July 30).

Zinc Supplementation. The COVID-19 Treatment Guidelines panel recommends against using zinc supplementation above the recommended dietary allowance for the prevention of COVID-19, except in a clinical trial.

Increased intracellular zinc concentrations impairs replication in a number of RNA viruses. Zinc has been shown to enhance cytotoxicity and induce apoptosis* when used in vitro with a zinc ionophore such as chloroquine. Chloroquine has also been shown to enhance intracellular zinc uptake in vitro. The relationship between zinc and COVID-19, including how zinc deficiency affects the severity of COVID-19 and whether zinc supplements can improve clinical outcomes, is currently under investigation (NIAID-RML, 202, July 30).

*Apoptosis: Apoptosis is the process of programmed cell death. It is a process that rids the body of cells that have been damaged beyond repair. Apoptosis also plays a role in preventing cancer.


Patients with severe COVID-19 can develop a systemic inflammatory response that can lead to lung injury and multisystem organ dysfunction. It has been proposed that the potent anti-inflammatory effects of corticosteroids might prevent or mitigate these deleterious effects. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial showed that the mortality rate was lower among patients who were randomized to receive dexamethasone than among those who received the standard of care. This benefit was observed in patients who required supplemental oxygen at enrollment. No benefit of dexamethasone was seen in patients who did not require supplemental oxygen at enrollment (NIAID-RML, 2020, August 27). 

Both beneficial and deleterious clinical outcomes have been reported with use of corticosteroids (mostly prednisone or methylprednisolone) in patients with other pulmonary infections. In patients with Pneumocystis jirovecii pneumonia and hypoxia, prednisone therapy reduced the risk of death; however, in outbreaks of other novel coronavirus infections (i.e., Middle East respiratory syndrome [MERS] and severe acute respiratory syndrome [SARS]), corticosteroid therapy was associated with delayed virus clearance. In severe pneumonia caused by influenza viruses, corticosteroid therapy appears to result in worse clinical outcomes, including secondary bacterial infection and death (NIAID-RML, 2020, August 27).

On July 30, 2020 the recommendations were updated to allow the use of alternative corticosteroids (i.e., hydrocortisone, methylprednisolone, prednisone) in situations where dexamethasone may not be available (NIAID-RML, 2020, July 30).

Chloroquine or Hydroxychloroquine

Chloroquine is an antimalarial drug that was developed in 1934. Hydroxychloroquine, an analogue of chloroquine, was developed in 1946 and is used to treat autoimmune diseases [e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis]. In general, hydroxychloroquine has fewer and less severe toxicities and fewer drug–drug interactions than chloroquine (NIAID-RML, 2020 July 30).

High-dose chloroquine has been associated with more severe toxicities than lower-dose chloroquine. A comparative trial compared high-dose chloroquine and low-dose chloroquine in patients with COVID-19; in addition, all participants received azithromycin, and 89% of the participants received oseltamivir. The study was discontinued early when preliminary results showed higher rates of mortality and QTc prolongation in the high-dose chloroquine group (NIAID-RML, 2020 July 30).

The COVID-19 Treatment Guidelines recommend against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19, except in a clinical trial. The panel recommends against the use of high-dose chloroquine for the treatment of COVID-19 (NIAID-RML, 2020, July 30).